A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: EZN-2208
Sponsor: Enzon Pharmaceuticals, Inc.